Abstract: An anti-Staphylococcus aureus antibody combination preparation comprising a) a toxin cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (HIa) and at least one of the bi-component toxins selected from the group consisting of HIg AB, HIg CB, LukSF, LukED, Luk S-HIg B, LukSD, HIg A-LukD, HIg A-LukF, Luk EF, LukE-HIg B, HIg C-LukD and HIg C-LukF; and b) an anti-Luk GH antibody; and/or c) an OPK antibody which recognizes a S. aureus surface protein thereby inducing OPK, specifically an anti-Ig-binding protein (IGBP) antibody comprising at least one CDR binding site recognizing any of the S. aureus Ig G binding domains of Protein A or Sbi.

Abstract: A monoclonal antibody that counteracts Staphylococcus aureus by specifically binding to wild-type immunoglobulin-binding proteins (IGBP) of S. aureus comprising a cross-specific CDR binding site recognizing at least three of the IGBP domains selected from the group consisting of Protein A (SpA) domains and immunoglobulin-binding protein (Sbi) domains SpA-A, SpA-B, SpA-C, SpA-D, SpA-E, Sbi-I, and Sbi-II, wherein the antibody has an affinity to bind SpA-E with a KD of less than 5×10?9M as determined by a standard optical interferometry method for a F(ab)2 fragment, and preferably binds to wt SpA equally or better compared to mutant SpA-KKAA that lacks binding to IgG Fc or VH3.

Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.

Abstract: The invention relates to a method for the prediction of S. aureus disease in a subject heavily colonized by S. aureus but not showing any symptom of S. aureus disease, said method comprising the step of determining the alpha haemolysin level in a biological sample of said subject as compared to a standard or reference control, wherein an elevated alpha haemolysin level or activity is indicative of the onset of S. aureus disease.

Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.